Antimicrobial stewardship program for neonates in Canada
Using Antibiotics Wisely - Development of National Neonatal Intensive Care Unit-specific ASP
This study is trying to improve how antibiotics are used in NICUs across Canada to help very-low-birth-weight infants stay healthier and reduce the risk of drug-resistant infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 22 Weeks to 44 Weeks |
| Sex | All |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT04388293 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop and implement antimicrobial stewardship strategies specifically for Neonatal Intensive Care Units (NICUs) across Canada. It will assess variations in antibiotic use and the prevalence of multi-drug resistant organisms (MDROs) among very-low-birth-weight infants. The study will analyze data from participating tertiary NICUs to identify correlations between antibiotic consumption and neonatal morbidity, with the goal of promoting optimal antibiotic use and reducing MDRO incidence. By focusing on this vulnerable population, the study seeks to enhance patient outcomes through improved antimicrobial practices.
Who should consider this trial
Good fit: Ideal candidates for this study are very-low-birth-weight infants admitted to participating tertiary NICUs in Canada.
Not a fit: Infants with major congenital anomalies will not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce the incidence of multi-drug resistant infections in neonates, leading to better health outcomes.
How similar studies have performed: Other studies have shown success with antimicrobial stewardship programs in various settings, indicating potential for positive outcomes in this context as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Very-low-birth-weight infants admitted to participating tertiary NICUs in Canada. Exclusion Criteria: * infants with major congenital anomalies
Where this trial is running
Edmonton, Alberta
- Royal Alexandra Hospital — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Study coordinator: Joseph Ting, Associate Prof
- Email: joseph.ting@ualberta.ca
- Phone: +1(780)248-5408
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.